Dr. Rini Describes Hypertension as a Biomarker

Dr. Brian I. Rini from the Taussig Cancer Institute Describes Hypertension as a Biomarker in RCC

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains results from the AXIS 1032 phase III trial comparing axitinib to sorafenib in the second-line setting for metastatic renal cell carcinoma (mRCC). Retrospective data from the study indicated hypertension as a marker of superior outcome.

Related Content:

OncLive TVOncology Business ManagementPrecision Medicine in Oncology®Genitourinary Cancers
OncLive’s September Roundup of Key FDA Approvals in Oncology
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer